Peptide Academy · Research use only

The Wild West is closing: the state of the peptide market

By BioLabs Research · Last reviewed October 2026

Peptide Academy · Chapter 7 of 7

Peptides went from textbooks to headlines, and online shops followed. Regulators have noticed. This chapter covers what has actually happened, in dated and sourced terms, what's approved and what isn't, and how to spot a serious supplier. It is general information, not legal advice.

The one rule that explains everything

In the US, whether a product is treated as a drug depends on its intended use, and regulators judge intended use from the whole picture: labels, websites, advertising and other statements made about the product ^[1].

So a lab chemical stays a lab chemical until someone markets it for people. Dose charts, "how to inject" guides, or "it'll fix your knee" claims can turn a "research only" product into an unapproved drug in a regulator's eyes.

What FDA has actually done

Warning letters to "research only" sellers

FDA has sent warning letters to online peptide sellers whose "research use only" labels didn't match their marketing:

• December 10, 2024: FDA issued warning letters to several online peptide sellers. In one, FDA wrote that despite statements such as "RESEARCH USE ONLY" and "INTENDED AS A RESEARCH CHEMICAL ONLY" on the product labeling, evidence from the seller's websites established that the products were intended to be drugs for human use, and called them unapproved new drugs ^[2].
• February 26, 2025: another letter said that despite statements such as "research use only," "not for human consumption" and "lab purposes only," evidence from the seller's website established that certain products were drugs intended for human use ^[3].

The pattern is consistent: a disclaimer doesn't override the marketing. FDA reads the website, and in these letters it also reviewed social media pages ^[2].

What's approved and what isn't

First, who this applies to. FDA approval and the compounding categories below are about drugs for patients: approved medicines dispensed on prescription, and drugs compounded by licensed pharmacies for individual prescriptions (section 503A) or by registered outsourcing facilities (503B). None of it applies to research-use-only (RUO) material, and none of it makes an RUO product legal for use in people. RUO products are neither approved drugs nor compounded drugs.

How the compounding lists work. While FDA builds its final list of bulk substances pharmacies may compound with, it sorts nominated substances into interim categories: Category 1 (under evaluation), Category 2 (raises significant safety risks) and Category 3 (nominated without adequate support) ^[6]. When a nominator withdraws, FDA moves the substance to a separate "nominated but withdrawn" table and keeps its safety notes there ^[4]. Category 1 is not approval ^[6].

"No approved application found" = no match in FDA's Drugs@FDA data (openFDA query, Oct 10, 2026). Coded compounds (G1-S, G2-T, G3-R) are not covered here. Lists change often; check the FDA pages for the current status.

For plain-English profiles of peptides that did become FDA-approved medicines, see FDA-Approved Peptides, Explained Simply.

The most regulated family

We treat receptor-signalling research compounds as the most regulated family in 2026. That's why, on our site, compounds in that group (G1-S, G2-T and G3-R) are listed under internal codes with identity and testing data only (Chapter 2).

Where the market is heading

We can't predict the future, but the direction of travel in the sources above is clear:

1. Marketing gets scrutinised. Regulators look at websites and social media, not just labels ^[2][3].
2. Paperwork becomes the product. Lot-specific certificates with both purity and identity data, from a named lab, are what separate serious suppliers (Chapter 4).
3. Search rewards sources that show their work. Google's own guidance says its systems aim to prioritise "helpful, reliable, people-first content", and encourages clear sourcing and showing who created the content ^[5].

Allowed vs. not allowed, at a glance

This is how we draw the line on our own site:

Your 7-point trust test for any supplier

1. Batch certificate available for the lot, matching the vial.
2. Both purity and identity tests (HPLC and mass spec, Chapter 5).
3. A named, identifiable testing lab and a test date.
4. A real company: legal name, contact details and policies.
5. No dosing advice. If a seller gives it, they're putting their own business, and your supply, at risk ^[2][3].
6. Clear shipping and returns policies.
7. No miracle language. Effect promises are exactly what regulators flag ^[1][2].

Where we stand

We'd rather be boring and here next year than exciting and shut down. We publish chemistry, testing and sourced research, and nothing more. Batch-specific certificates of analysis are available on request. See our catalog: BPC-157, TB-500, GHK-Cu, MOTS-c, Semax, AOD-9604 and NAD+. For more, see are peptides legal?.

Frequently asked questions

Does a "research use only" label make a product legal? Not by itself. FDA warning letters show the agency looks at the seller's website and marketing, not just the label, to decide whether a product is intended for human use.

Are any of these peptides FDA-approved drugs? Of the compounds in this series, only Tesamorelin has an FDA approval (application 022505), as a prescription medicine. That approval doesn't apply to research-use-only material.

How can I tell if a peptide supplier is trustworthy? Look for lot-matched certificates with purity and identity data from a named lab, a real company with clear policies, no dosing advice and no miracle claims.

Is this legal advice? No. This chapter summarises public FDA documents for general education.

Series navigation: ← Chapter 6: Basic terms · Back to the Peptide Academy hub · Start again: Chapter 1

For laboratory research use only. Not for human or veterinary use. Not a drug, food, cosmetic or dietary supplement. Nothing on this page is medical or legal advice.

References

1. 21 CFR 201.128, Meaning of "intended uses" (eCFR). ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-A/section-201.128
2. FDA Warning Letter, MARCS-CMS 695607, December 10, 2024. FDA warning letters database: fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
3. FDA Warning Letter, MARCS-CMS 696885, February 26, 2025. FDA warning letters database: fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
4. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of 04/22/2026. fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
5. Google Search Central. Creating helpful, reliable, people-first content. developers.google.com/search/docs/fundamentals/creating-helpful-content
6. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (categories 1–3), updated May 14, 2026. fda.gov/media/94155/download
7. FDA, Drugs@FDA: application 022505 (tesamorelin acetate), overview and approval history. accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505
8. FDA, Drugs@FDA data via openFDA (api.fda.gov/drug/drugsfda.json), queried Oct 10, 2026 by generic, substance and active-ingredient name; query log on file
9. FDA. Certain Bulk Drug Substances… That May Present Significant Safety Risks, content current as of 09/27/2024 (category 2 table with "date added"; archived copy web.archive.org/web/20250120011449/https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)